Vasculitis Pipeline and Clinical Trial Assessment 2023: FDA Approvals, Symptoms, Treatment, Therapies and Drugs, Companies and Competitive Intelligence by DelveInsight | CytoDyn, ChemoCentryx, Roche, GlaxoSmithKline, Vifor Pharma, Abbvie, Lilly and others

(New York, USA) DelveInsight's 'Vasculitis Pipeline Insight 2023' report provides comprehensive global coverage of available, marketed, and pipeline Vasculitis therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Vasculitis pipeline domain.
For Vasculitis emerging drugs, the Vasculitis pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.

Request a sample and discover the recent breakthroughs happening Vasculitis pipeline landscape @ https://www.delveinsight.com/report-store/vasculitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Key Takeaways from the Vasculitis Pipeline Report
• 30+ Vasculitis pipeline therapies are in various stages of development, and their anticipated acceptance in the Vasculitis market would significantly increase market revenue.
• Leading 20+ Vasculitis companies developing novel drug candidates to improve the Vasculitis treatment landscape, including CytoDyn, ChemoCentryx, Hoffman-la-Roche, GlaxoSmithKline, Vifor Pharma, R-Pharm Overseas, Abbvie, Toleranzia, Ambulero, Visterra, Beijing Defengrei Biotechnology, InflaRx, Janssen Biotech, Novartis, AbbVie, Oxitope Pharma, InflaRx, Eli Lilly and Company, Toleranzia, Travere Therapeutics, Caladrius Biosciences, Caladrius Biosciences, Yake Biotechnology, and others.
• Promising Vasculitis pipeline therapies in various stages of development include AMB 301, Research, program: kidney disorder therapeutics, BDB 1, Vilobelimab, Guselkumab, Secukinumab, Upadacitinib, CCX-168, Belimumab, and others.
• In October 2021, Novartis Pharmaceuticals initiated a randomized, parallel-group, double-blind, placebo-controlled multicenter Phase III trial to investigate the efficacy and safety of Secukinumab 300 mg administered subcutaneously versus placebo, in combination with glucocorticoid taper regimen, in patients With Giant Cell Arteritis (GCA)
• Chemocentryx has launched TAVNEOS in the fourth quarter of 2021 following FDA approval on October 8, 2021, as an adjunctive treatment in adult patients with severe active ANCA-associated vasculitis, specifically granulomatosis polyangiitis (GPA) or microscopic polyangiitis (MPA), the two main forms of ANCA-associated vasculitis, in combination with standard therapy including glucocorticoids.
• ChemoCentryx received approval from European Union (EU) for its drug, Tavneos (avacopan), to treat adult patients with anti-neutrophil cytoplasmic autoantibody-associated vasculitis (ANCA-associated vasculitis) in January 2022.
Request a sample and discover the recent breakthroughs happening Vasculitis pipeline landscape @ https://www.delveinsight.com/sample-request/vasculitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Vasculitis Overview
Vasculitis involves inflammation of the blood vessels. The inflammation can cause the walls of the blood vessels to thicken, which reduces the width of the passageway through the vessel. If blood flow is restricted, it can damage organs and tissue. Vasculitis can affect people at any age. Some forms affect blood vessels that go to or supply specific organs like your skin, eyes, or brain. Vasculitis symptoms are commonly observed, such as fever, loss of appetite, weight loss, and fatigue.
The most common forms of Vasculitis are Giant cell arteritis, Polymyalgia rheumatica, Polyarteritis nodosa, and Granulomatosis with polyangiitis. Whereas different types of Vasculitis are Large Vessel Vasculitis, Medium Vessel Vasculitis, and Small Vessel Vasculitis. Vasculitis treatment depends on what's causing your Vasculitis and which organs are affected. Corticosteroid medications, also known as steroids, are generally preferred to fight inflammation.

Vasculitis Pipeline Therapies and Key Companies
• AMB 301: Ambulero
• Research program: Kidney Disorder Therapeutics: Visterra
• BDB 1: Beijing Defengrei Biotechnology
• Vilobelimab: InflaRx
• Guselkumab: Janssen Biotech
• Secukinumab: Novartis
• Upadacitinib: AbbVie

Learn more about the Vasculitis emerging pipeline therapies @ https://www.delveinsight.com/sample-request/vasculitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Vasculitis Pipeline Therapeutics Assessment
By Product Type
• Monotherapy
• Combination Therapy
By Stage
• Discovery
• Pre-Clinical
• Phase I
• Phase II
• Phase III
• Pre-registration
By Route of Administration
• Oral
• Intravenous
• Inhalation
• Subcutaneous
By Molecule Type
• Gene therapy
• Stem cell therapy
• Small molecules

Scope of the Vasculitis Pipeline Report
• Coverage: Global
• Key Vasculitis Companies: CytoDyn, ChemoCentryx, Hoffman-la-Roche, GlaxoSmithKline, Vifor Pharma, R-Pharm Overseas, Abbvie, Toleranzia, Ambulero, Visterra, Beijing Defengrei Biotechnology, InflaRx, Janssen Biotech, Novartis, AbbVie, Oxitope Pharma, InflaRx, Eli Lilly and company, Toleranzia, Travere Therapeutics, Caladrius Biosciences, Caladrius Biosciences, Yake Biotechnology, and others.
• Key Vasculitis Pipeline Therapies: AMB 301, Research, program: kidney disorder therapeutics, BDB 1, Vilobelimab, Guselkumab, Secukinumab, Upadacitinib, CCX-168, Belimumab, and others.

Dive deep into rich insights for Vasculitis emerging therapies and assessment; visit @ https://www.delveinsight.com/sample-request/vasculitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Table of Contents
1. Introduction
2. Vasculitis Executive Summary
3. Vasculitis Overview
4. Vasculitis Pipeline Therapeutics
5. Vasculitis Pipeline: Late Stage Products (Phase III)
6. Vasculitis Pipeline: Mid Stage Products (Phase II)
7. Vasculitis Pipeline: Early Stage Products (Phase I/II)
8. Vasculitis Pipeline: Preclinical Stage Products
9. Vasculitis Pipeline: Discovery Stage Products
10. Vasculitis Pipeline Therapeutic Assessment
11. Vasculitis Pipeline: Inactive Products
12. Collaborations Assessment- Licensing / Partnering / Funding
13. Vasculitis Unmet Needs
14. Vasculitis Market Drivers and Barriers
15. Appendix
16. About DelveInsight

For further information on the Vasculitis current pipeline therapeutics, reach out @ https://www.delveinsight.com/sample-request/vasculitis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=apr

Trending Report:
• Adrenal Cortex Neoplasms Market: https://www.delveinsight.com/report-store/adrenal-cortex-neoplasms-market
• Hypothalamic Obesity Market: https://www.delveinsight.com/report-store/hypothalamic-obesity-market
• Pediatric Growth Hormone Deficiency Pghd Market: https://www.delveinsight.com/report-store/pediatric-growth-hormone-deficiency-market
• Chronic Rhinosinusitis Phenotype With Nasal Polyps Market: https://www.delveinsight.com/report-store/chronic-rhinosinusitis-phenotype-with-nasal-polyps-market-insight
• Hpv-induced Cancers Market: https://www.delveinsight.com/report-store/hpv-induced-cancers-market
• Pain Management Devices Market: https://www.delveinsight.com/report-store/pain-management-devices-market
• Hyperhidrosis Market: https://www.delveinsight.com/report-store/hyperhidrosis-market
• Bronchial Spasm Market: https://www.delveinsight.com/report-store/bronchial-spasm-market
• Alopecia Market: https://www.delveinsight.com/report-store/alopecia-market
• Cervical Intraepithelial Neoplasia Market: https://www.delveinsight.com/report-store/cervical-intraepithelial-neoplasia-market

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: info@delveinsight.com
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.